Any other usage requires independent regulatory compliance
However, in the US, UK, and many parts of Europe, the patent protection for semaglutide would last till 2031 and beyond, as they have patent term extension mechanisms that can be used to extend the protection period
Injection-Site Reactions Redness, tenderness, swelling, itching, or irritation may occur around a subcutaneous injection site
Recently, the SELECT trial assessed the impact of semaglutide on cardiovascular outcomes in overweight and obese patients without diabetes but with established CVD
Its hard to spot when theyre not telling the whole truth
Acta Diabetol (2020) 57:36775